SCHEMBL3406206

SCHEMBL3406206

Cc1cc2c(CCC(=O)O)cccc2o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.46
PARP1 P09874 1/20 0.44
SLC6A3 Q01959 1/20 0.44
PTGER1 P34995 1/20 0.43
PTGER4 P35408 1/20 0.43
PTGER3 P43115 1/20 0.43
PTGER2 P43116 1/20 0.43
MAPT P10636 1/20 0.42
MTNR1A P48039 5/20 0.42
MTNR1B P49286 5/20 0.42
MCL1 Q07820 2/20 0.42
FFAR1 O14842 2/20 0.42
FFAR4 Q5NUL3 1/20 0.42
RXRA P19793 2/20 0.40
RXRB P28702 2/20 0.40
RXRG P48443 2/20 0.40
NR4A2 P43354 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16047568 0.80 FFAR4 (0.43) PTGER1PTGER4PTGER3PTGER2FFAR1
SCHEMBL6676825 0.77 MEN1 (0.39) MCL1KDM4E
SCHEMBL4867269 0.75 PARP1 (0.47) NPSR1PARP1PTGER1PTGER4PTGER3
SCHEMBL5696745 0.74 PARP1 (0.69) NPSR1PARP1SLC6A3PTGER1PTGER4
SCHEMBL3798516 0.74 ALOX5 (0.57) NPSR1PARP1PTGER1PTGER4PTGER3
SCHEMBL17841422 0.74 CYP1A2 (0.37) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL7250151 0.73 MTNR1A (0.48) NPSR1PARP1PTGER1PTGER4PTGER3
SCHEMBL496357 0.72 CA12 (0.44) NR4A2KDM4EALDH1A1HPGDTSHR
SCHEMBL13992152 0.72 NPSR1 (0.57) NPSR1SLC6A3PTGER4MAPTKDM4E
SCHEMBL3405010 0.71 POLB (0.46) NPSR1SLC6A3FFAR1FFAR4RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311778-A1 CHROMANE DERIVATIVES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2010-12-09 US disclosed
EP-2254879-A2 CHROMANE DERIVATIVES AS TRPV3 MODULATORS Glenmark Pharmaceuticals S.A. (CH) 2010-12-01 EP disclosed
WO-2009084034-A2 CHROMANE DERIVATIVES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS, S. A. (CH) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311778-A1 CHROMANE DERIVATIVES AS TRPV3 MODULATORS TRPV3, TRPV2, TRPV1 NPSR1 489/4885PARP1 4286/4885SLC6A3 673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.